• Contact

  • Newsletter

  • About us

  • Delivery options

  • Prospero Book Market Podcast

  • The Triptans: Novel Drugs for Migraine: Novel Drugs for Migraine

    The Triptans: Novel Drugs for Migraine by Humphrey, Patrick; Ferrari, Michel; Olesen, Jes;

    Novel Drugs for Migraine

    Series: Frontiers in Headache Research series; 10;

      • GET 10% OFF

      • The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
      • Publisher's listprice GBP 277.50
      • The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.

        132 575 Ft (126 262 Ft + 5% VAT)
      • Discount 10% (cc. 13 258 Ft off)
      • Discounted price 119 318 Ft (113 636 Ft + 5% VAT)

    132 575 Ft

    db

    Availability

    printed on demand

    Why don't you give exact delivery time?

    Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.

    Product details:

    • Publisher OUP Oxford
    • Date of Publication 1 November 2001

    • ISBN 9780192632142
    • Binding Hardback
    • No. of pages358 pages
    • Size 247x172x24 mm
    • Weight 813 g
    • Language English
    • Illustrations Numerous graphs and line figures
    • 0

    Categories

    Short description:

    A new era in the treatment of migraine headache arrived with the development of a revolutionary class of drugs known as the triptans. The book reviews the development, pharmacology, mechanisms of action, efficacy and tolerability of the full range of triptans, and will help the clinician to make a logical choice about which triptan to use for which patient.

    More

    Long description:

    A new era in the treatment of migraine headache arrived with development of a revolutionary class of drugs known as the triptans.

    The book describes the development of this class of drugs, starting with the discovery of sumatriptin, covers the pharmacology and the mechanisms of action of the full range of triptans, before comparing their clinical efficacy and tolerability. Each drug is described by the company who produces it and then reviewed, based on experimental and clinical evidence, by independent scientists.

    This comprehensive review will provide clinicians with guidance on which triptan to select for which patient.

    The editors have gathered together the leading international experts to produce a book that will appeal to all neurologists and general physicians caring for headache patients as well as those with research interests in the field.

    More

    Table of Contents:

    Section I - Background and early development
    The discovery of sumatriptan and a new class of drugs for the acute treatment of migraine
    5-HT receptors in brain and vasculature
    Structural and operational diversity of Serotonin receptors. Potential relevance to migraine pathophysiology and treatment
    Characterisation of 5-HT1 receptor expression in human vasculature
    5-HT1B and 5-HT1D receptor immunoreactivity colocalize with sensory neurotransmitters in the human trigeminal ganglion
    Upregulation of 5-HT1B/1D receptors during organ culture of cerebral arteries
    Background and early development - discussion summary
    Section II - Pharmacology of the triptans
    Clinical pharmacokinetics of the triptans:what are the important clinical issues?
    Pharmacodynamics of triptans
    Characteristics of different routes of administration
    Encapsulation of sumatriptan does not delay its absorption
    Synergism of 5-HT1 and 5-HT2 receptors in sumatriptan-induced vasocontractile response in rabbit common carotid artery
    Role of 5-HT1B and 5HT1D receptors in sumatriptan mediated vasocontractile response in rabbit common carotid artery
    Comparison of triptan induced contractions in human cerebral vs coronary arteries
    Pharmacological analysis of cotractile effects of eletriptan and sumatriptan on human isolated blood vessels
    Pharmacology of the triptans: discussion summary
    Section III - Antimigraine actions of the triptans
    The importance of vasoconstriction in the mechanism of the antimigraine action of the triptans
    Inhibition of neurogenic inflammation is most important
    Central nervous system effects are most important
    Do we really understand how triptans work?
    The relevance of hepatic intrinsic clearance and brain penetration on the doses used for 5-HT agonists (triptans) in the treatment of migraine
    In vivo serotonergic effects and extracellular brain levels of centrally and systemically administered eletriptan, zolmitriptan and sumatriptan
    Regulation of capsaicin-evoked CGRP release from rat dural sensory neurones in vitro
    Arterial distensibility in ergotamine and sumatriptan abuse
    Anti migraine actions of the triptans: discussion summary
    Section IV - Clinical efficacy and tolerability of the triptans
    Sumatriptan: looking back and looking forward
    Zolmitriptan offers doctor and patient choices for effective treatment of migraine
    Rizatriptan: clinical update
    Evidence against tight correlation between chest oppressive symptoms and ischaemic coronary changes after subcutaneous sumatriptan injection
    Alteration in cluster headache during subcutaneous administration of sumatriptan
    Efficacy and tolerability of rizatriptan 10mg in migraine: experience with 70527 patient episodes
    Consistency of pain relief over multiple migraine attacks following treatment with rizatriptan
    Naratriptan: the gentle triptan
    Experience with eletriptan (RelpaxTM)
    Almotriptan
    Frovatriptan: simplifying clinical practice in migraine
    The cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease during a migraine attack
    Lack of clinically significant interactions between frovatriptan and ergotamine, propranolol or moclobemide
    Frovatriptan pharmocokinetics are unaffected during a migraine attack
    Clinical efficacy and tolerability of the triptans: discussion summary
    Section V - The triptans in clinical practice
    Acute management of migraine: clinical trials of triptans versus other agents
    Which triptans for which patient?
    The Framig 99 survey III: therapeutical behaviour of migraineurs
    Migraine in France in 2000: therapeutical data
    The triptan threshold score: a score tohelp patients identify the best moment to take the triptan
    Triptan plus NSAID with long half life: increase of efficacy and reduction of headache recurrence in acute migraine
    Comparison of the triptans with other drugs in the development of drug-induced headache
    An epidemiological study on the differences between sumatriptan and ergotamine overuse
    Overuse of new 5-HT agonists (zolmitriptan and naratriptan) in migraine patients: clinical features
    The triptans in clinical practice: discussion summary

    More
    0